Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008;11(4):214-8.
doi: 10.1007/s10120-008-0485-4. Epub 2009 Jan 8.

Recurrence in early gastric cancer with lymph node metastasis

Affiliations

Recurrence in early gastric cancer with lymph node metastasis

Makoto Saka et al. Gastric Cancer. 2008.

Abstract

Background: Early gastric cancer (EGC) has an excellent prognosis, but some patients with lymph node-positive disease will develop recurrence. In this study we investigated the risk factors for recurrence in this selected group of patients.

Methods: The clinical and pathological records of 2368 patients who underwent gastrectomy for solitary EGC between 1980 and 1999 at the National Cancer Center Hospital, Tokyo, were examined. Two hundred and thirty-eight patients (10%) were lymph node-positive (positive for lymph node metastasis) and form the population of this study.

Results: Nineteen (8%) of the 238 patients with lymph node-positive disease developed recurrence. The most common site of recurrence was lymph node (37%), followed by liver (21%). The interval between surgery and the detection of recurrence ranged from 3 to 98 months, with a median of 26 months. Multivariate analysis demonstrated that the number of metastatic nodes was an independent risk factor for recurrence. Patients with seven or more metastatic nodes had the highest rate of recurrence, at 38%.

Conclusion: The number of nodes positive for metastasis was the only independent risk factor for recurrence after curative surgery in patients with lymph node-positive early gastric cancer. These high-risk patients may obtain additional survival benefit if targeted with adjuvant chemotherapy.

PubMed Disclaimer

References

    1. Jpn J Clin Oncol. 2001 Oct;31(10):495-9 - PubMed
    1. Lancet. 1999 Jul 24;354(9175):273-7 - PubMed
    1. Br J Surg. 2007 Dec;94(12):1468-76 - PubMed
    1. J Am Coll Surg. 2005 Jan;200(1):15-9 - PubMed
    1. Lancet. 1996 Apr 13;347(9007):995-9 - PubMed

MeSH terms

LinkOut - more resources